Skip to main content
SpringerLink
Log in

Diagnosis

  • Chapter
  • First Online:
Handbook of Chronic Myeloid Leukemia

  • 1336 Accesses

Abstract

When a patient presents with suspected chronic myeloid leukemia (CML) appropriate assessments are needed to confirm the diagnosis and stage of disease, and to assign a risk score to that patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia. 1994;8:208-211.

    Google Scholar 

  2. Buesche G, Ganser A, Schlegelberger B, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia. 2007;21:2420-2427.

    Google Scholar 

  3. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.

    Google Scholar 

  4. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101:3794-3800.

    Google Scholar 

  5. O’Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100:1628-1633.

    Google Scholar 

  6. Saikia T, Advani S, Dasgupta A, et al. Characterisation of blast cells during blastic phase of chronic myeloid leukaemia by immunophenotyping--experience in 60 patients. Leuk Res. 1988;12:499-506.

    Google Scholar 

  7. Khalidi HS, Brynes RK , Medeiros LJ, et al. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in “lymphoid” blasts and A comparison of morphologic, immunophenotypic, and molecular findings. Mod Pathol. 1998;11:1211-1221.

    Google Scholar 

  8. Swerdlow S, Campo W, Harris N, et al, eds. WHO Classification of Tumours of Haematopoeitic and Lymphoid Tissues. Lyon: IARC; 2008.

    Google Scholar 

  9. Marzocchi G, Castagnetti F, Luatti S, et al. Variant Philadelphia translocations: molecularcytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011;117:6793-6800.

    Google Scholar 

  10. Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118:6760-6768.

    Google Scholar 

  11. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.

    Google Scholar 

  12. Branford S, Hughes TP. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. In: Iland HJ, Hertzberg M, Marlton P, eds. Myeloid Leukemia: Methods and Protocols, Methods in Molecular Medicine. Totawa, NJ: Humana Press; 2006:69-92.

    Google Scholar 

  13. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8:186-189.

    Google Scholar 

  14. de la Fuente J, Merx K, Steer EJ, et al. ABL -BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood. 2001;98:2879-2880.

    Google Scholar 

  15. Rozman C, Urbano-Ispizua A, Cervantes F, et al. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia. 1995;9:1104-1107.

    Google Scholar 

  16. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol. 1995;89:546-554.

    Google Scholar 

  17. Saussele S, Weisser A, Muller MC, et al. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia. 2000;14:2006-2010.

    Google Scholar 

  18. Branford S, Hughes TP, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. Br J Haematol. 2002;117:875-877.

    Google Scholar 

  19. Morris SW, Daniel L, Ahmed CM, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood. 1990;75:2035-2041.

    Google Scholar 

  20. Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002;21:8652-8667.

    Google Scholar 

  21. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368:1781-1790.

    Google Scholar 

  22. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.

    Google Scholar 

  23. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ≪ good-risk ≫ chronic granulocytic leukemia. Blood. 1984;63:789-799.

    Google Scholar 

  24. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432.

    Google Scholar 

  25. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.

    Google Scholar 

  26. Kantarjian HM, Smith TL , McCredie KB , et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985;66:1326-1335.

    Google Scholar 

  27. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-858.

    Google Scholar 

  28. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686-692.

    Google Scholar 

  29. Hoffmann VS, Baccarani M, Lindoerfer D, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27:2016-2022.

    Google Scholar 

  30. Jabbour E, Cortes J, Nazha A, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012;119:4524-4526.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SA Pathology, Department of Haematology, Centre for Cancer Biology, Adelaide, South Australia, Australia

    Timothy P Hughes

  2. Department of Haematology, Flinders University and Medical Centre and School of Medicine, University of Adelaide, Adelaide, South Australia, Australia

    David M Ross

  3. University of Adelaide, Department of Haematology, Adelaide, Australia

    Junia V Melo

Authors
  1. Timothy P Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junia V Melo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy P Hughes .

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hughes, T.P., Ross, D.M., Melo, J.V. (2014). Diagnosis. In: Handbook of Chronic Myeloid Leukemia. Adis, Cham. https://doi.org/10.1007/978-3-319-08350-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08350-6_2

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08349-0

  • Online ISBN: 978-3-319-08350-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation